JointHealth™ express   November 29, 2006

Health Canada has approved lumiracoxib (Prexige®) for use in the treatment of osteoarthritis of the knee in adults. Lumiracoxib (Prexige®) was issued its Notice of Compliance (NOC) on November 2, 2006.

The knee is the large joint most commonly affected by osteoarthritis, so this is good news for Canadians living with the disease as it expands the treatment arsenal available to health-care providers and patients.

This medication is known as a COX-2 inhibitor, which works by selectively blocking the COX-2 enzyme. COX-2 inhibitors are non-steroidal anti inflammatory drugs (or "NSAIDs"), and may have a lower risk of gastrointestinal side-effects than traditional NSAIDs, but may also increase cardiovascular (heart) side effects in those at risk.

To learn if lumiracoxib (Prexige®) or another osteoarthritis treatment may be helpful to you, please speak to your rheumatologist or other health care provider helping you to manage your disease.

To view the Notice of Compliance, please visit and search for "Prexige".